Global Growth Forecast Downgrade and Economic Uncertainty: The IMF's anticipated downgrade of global growth forecasts due to the Middle East conflict creates a challenging environment for growth-oriented biotech companies like Adaptive Biotechnologies. Reduced global growth often translates to tighter capital markets and decreased investor appetite for riskier assets, potentially impacting ADPT's access to funding for R&D and expansion.

Inflationary Pressures and Interest Rate Environment: Strong US job growth can fuel inflation concerns, potentially leading the Federal Reserve to maintain higher interest rates. Higher rates negatively affect biotechnology stocks by increasing the cost of capital and discounting future earnings at a higher rate, especially for companies like ADPT that are not yet consistently profitable.

Biotechnology Sector-Specific Headwinds/Tailwinds: The broader biotechnology sector, where ADPT operates, is highly sensitive to regulatory developments, clinical trial outcomes, and overall investor sentiment towards healthcare innovation. Global economic uncertainty from rising oil prices and geopolitical conflict could make investors more cautious about pre-profit biotech firms, leading to decreased valuations and investment flows.